1,058,378 Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 1,058,378 shares of the company’s stock, valued at approximately $6,192,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. SG Americas Securities LLC bought a new stake in Voyager Therapeutics during the 2nd quarter valued at $85,000. SummerHaven Investment Management LLC lifted its position in shares of Voyager Therapeutics by 2.5% during the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after acquiring an additional 1,921 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Voyager Therapeutics by 17.7% in the second quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after acquiring an additional 44,289 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC purchased a new position in shares of Voyager Therapeutics in the second quarter valued at $1,012,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $6.93 on Tuesday. The company’s fifty day moving average price is $6.53 and its 200-day moving average price is $7.28. The firm has a market capitalization of $378.59 million, a price-to-earnings ratio of 9.76 and a beta of 0.90. Voyager Therapeutics, Inc. has a one year low of $5.19 and a one year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the prior year, the firm earned ($0.59) earnings per share. As a group, equities research analysts expect that Voyager Therapeutics, Inc. will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

VYGR has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 18th. Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday. They set a “buy” rating and a $12.00 target price on the stock. Wedbush began coverage on shares of Voyager Therapeutics in a research note on Friday. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics has an average rating of “Buy” and an average price target of $17.00.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.